Selegiline augmentation of antipsychotics for the treatment of negative symptoms in schizophrenia

Treatments for schizophrenia: a critical review of pharmacology and mechanisms of action of antipsychotic drugs

“…Selegiline (deprenyl) is a monoamine oxidase (MAO)-B inhibitor that selectively enhances Although several case series reported the beneficial effects of selegiline on negative symptoms of schizophrenia, [342][343][344] one double-blind, controlled study of the agent as adjunct to antipsychotic treatment failed to offer therapeutic benefit. 345 The selective irreversible MAO-B inhibitors, selegiline and rasagiline, have been shown to possess neuroprotective activities in cell culture and in vivo models of Parkinson's disease (for a review, see Maruyama et al 346 ).…”

The Role of Selegiline in the Treatment of Negative Symptoms Associated with Schizophrenia

“…11 All patients demonstrated a good response to antipsychotic therapy for positive symptoms but had prominent residual negative symptoms. Patients were evaluated at baseline and between 2 and 8 months after the initiation of selegiline.…”

“…One case report, 2 open-label studies, and 2 placebo-controlled studies were found that evaluated the efficacy of low-dose (10-15 mg) oral selegiline for the treatment of negative symptoms associated with schizophrenia. [11][12][13][14][15] Case Report…”

Selegiline in the Treatment of Negative Symptoms of Schizophrenia

“…Several open label trials have been promising (Gupta et al, 1999;Bodkin et al, 1996;Perenyi et al, 1991), but two small, brief placebo-controlled trials yielded negative results (Jungerman et al, 1999;Goff et al, 1993). Several open label trials have been promising (Gupta et al, 1999;Bodkin et al, 1996;Perenyi et al, 1991), but two small, brief placebo-controlled trials yielded negative results (Jungerman et al, 1999;Goff et al, 1993).…”

“…The first trial was conducted with 13 male chronic schizophrenic patients who were given selegiline to on-going neuroleptic treatment (Perenyi et al, 1992). Subsequently Gupta and colleagues published a case series including three patients in continuing day treatment, who each received low-dose selegiline augmentation of on-going antipsychotic treatment (Gupta et al, 1999). A second study was published in 1996, with 21 patients meeting criteria for schizophrenia or schizoaffective disorder who displayed prominent negative symptoms (Bodkin et al, 1996).…”